Allergen immunotherapy: Current and new therapeutic strategies

Allergology International

Volumn 51, Issue 4, 2002, Pages 221-231

  Rolland, Jennifer M ^a,c   O'Hehir, Robyn E ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

Author keywords

Allergen; IgE; Immunotherapy; T cell

Indexed keywords

ALLERGEN;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGENICITY; ASTHMA; CHEMICAL MODIFICATION; CLINICAL PRACTICE; CLINICAL RESEARCH; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; EOSINOPHIL; EPITOPE MAPPING; HELPER CELL; HUMAN; IMMUNOGLOBULIN GENE; IMMUNOMODULATION; IMMUNOTHERAPY; INTOXICATION; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; REVIEW; RHINOCONJUNCTIVITIS; RISK ASSESSMENT; STANDARDIZATION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 0036967093     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1592.2002.00272.x     Document Type: Review

References (81)

1. Kay AB. Allergy and allergic diseases. N. Engl. J. Med. 2001; 344: 30-7.
2. Romagnani S. Lymphokine production by human T cells in disease states. Annu. Rev. Immunol. 1994; 12: 227-52.
3. Malling H-J. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53: 461-72.
4. Noon L. Praphylactic inoculation against hayfever. Lancet 1911; i: 1572-3.
5. Freeman J. Vaccination against hayfever: Report of results during the first three years. Lancet 1914; i: 1178.
6. Bousquet J, Lockey RF, Malling H-J. WHO position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. Allergy 1998; 53 (Suppl. 44): 1-42.
7. Des Raches A, Paradis L, Menardo J-L, Bauges S, Daures J-P, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract VI. Specific immunotherapy prevents the onset of new sensitizatians in children. J. Allergy Clin. Immunol. 1997; 99: 450-3.
8. Purello-D'ambrosio F, Gangemi S, Merendino RE et al. Prevention of new sensitizations in monosensitized subjects, submitted to specific immunotherapy or not. A retrospective study. Clin. Exp. Allergy 2001; 31: 1295-302.
9. Jacobsen L, Dreborg S, Moller C et al. Immunotherapy as a preventative treatment. J. Allergy Clin. Immunol. 1996; 97: 232 (Abstract).
10. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 2002; 109: 251-6.
11. Adkinson NF, Eggleston PA, Eney D et al. A controlled trial of immunotherapy for asthma in allergic children. N. Engl. J. Med. 1997; 336: 324-31.
12. Rolland JR, Douglass JA, O'Hehir RE. Allergen immunotherapy: Current and new therapeutic strategies. Exp. Opin. Invest. Drugs 2000; 9: 515-27.
13. Malling H-J, Abreu-Nogueira J, Alvarez-Cuesta E et al. Position paper: Local Immunotherapy. Allergy 1998; 53: 933-44.
14. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 2000; 2: CD001186.
15. Lerch E, Muller U. Long-term protection after stopping VIT: Results of restings in 200 patients. J. Allergy Clin. Immunol. 1998; 101: 606-12.
16. Durham SR, Walker S, Varga E-M et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 1999; 341: 468-75.
17. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am. J. Respir. Crit. Care Med. 1995; 151: 969-74.
18. Varney VA, Edwards J, Tabbah K et al. Clinical efficacy of specific immunotherapy to cat dander: A double-blind placebo-controlled trial. Clin. Exp. Allergy 1997; 27: 860-7.
19. Frew AJ. Injection immunotherapy. BMJ 1993; 307: 919-23.
20. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: A six-year prospective study. J. Allergy Clin. Immunol. 1982; 70: 261-71.
21. Creticos PS, Van Metre TE, Mardiney MR Dose of response of IgE and IgG antibodies during ragweed immunotherapy. J. Allergy Clin. Immunol. 1984; 73: 94-104.
22. Djurup DBK, Malling H, Sondergard I et al. The IgE and IgG subclass antibody response in patients allergic to yellow jacket venom undergoing different regimens of venom immunotherapy. J. Allergy Clin. Immunol. 1985; 76: 46-55.
23. Djurup DBK, Malling H. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin. Allergy 1987; 17: 459-68.
24. Muller U, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honeybee venom. Allergy 1989; 44: 412-8.
25. Ball T, Sperr WR, Valent P et al. Induction of antibody responses to new B-cell epitopes indicates vaccination character of allergen immunotherapy. Eur. J. Immunol. 1999; 29: 2026-36.
26. Van Neerven RJJ, Wikborg T, Lund G et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol. 1999; 163: 2944-52.
27. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J. Allergy Clin. Immunol. 1996; 97: 1356-65.
28. D'Amato G, Liccardi G, Russo M, Saggese M, D'Amato M. Measurement of serum levels of eosinophil cationic protein to monitor patients with seasonal respiratory allergy induced by Parietaria pollen (treated and untreated with specific immunotherapy). Allergy 1996; 51: 245-50.
29. Hsieh KH, Ng CK. Increased plasma platelet-activating factor in children with acute asthmatic attacks and decreased in vivo and in vitro production of platelet-activating factor after immunotherapy. J. Allergy Clin. Immunol. 1993; 91: 650-7.
30. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J. Clin. Invest. 1993; 92: 644-51.
31. Rolland JR, O'Hehir RE. Immunotherapy of allergy: Anergy, deletion, and immune deviation. Curr. Opin. Immunol. 1998; 10: 640-5.
32. Akdis CA, Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy 2000; 55: 222-30.
33. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest. 1998; 102: 98-106.
34. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2 to Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur. J. Immunol. 1997; 27: 1131-9.
35. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J. Allergy Clin. Immunol. 1997; 99: 254-60.
36. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza haemagglutinin. J. Exp. Med. 1983; 157: 1434-47.
37. Mueller DL, Jenkins MK, Schwartz RH. An accessory cell-derived costimulatory signal acts independently of protein kinase C activation to allow T cell proliferation and prevent the induction of unresponsiveness. J. Immunol. 1989; 142: 2617-28.
38. Tovey ER, Chapman MD, Wells CW, Platts-Mills TA. The distribution of dust mite allergen in the houses of patients with asthma. Am. Rev. Respir. Dis. 1981; 124: 630-5.
39. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 1996; 98: 1676-83.
40. Akdis CA, Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: Two key steps in specific immunotherapy. FASEB J. 1999; 13: 603-9.
41. Kabelitz D, Pohl T, Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol. Today 1993; 14: 338-9.
42. Guerra F, Carracedo J, Madueno J-A, Sanchez-Guijo P, Ramirez R. Allergens induce apoptosis in lymphocytes from atopic patients. Hum. Immunol. 1999; 60: 840-7.
43. Guerra F, Carracedo J, Solana-Lara R, Sanchez-Guijo P, Ramirez R. Th2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis after culture with specific allergens. J. Allergy Clin. Immunol. 2001; 107: 647-53.
44. Mollereau B, Blanchard D, Deas O et al. Relationship between proliferation and susceptibility to CD95- and CD2-mediated apoptosis in stimulated primary T lymphocytes. J. Immunol. 1997; 159: 2668-77.
45. O'Hehir RE, Yssel H, Verma S, de Vries JE, Spits H, Lamb JR. Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int. Immunol. 1991; 3: 819-26.
46. Carballido JM, Faith A, Carballido-Perrig N, Blaser K. The intensity of T cell receptor engagement determines the cytokine pattern of human allergen-specific T helper cells. Eur. J. Immunol. 1997; 27: 515-21.
47. Rolland JM, O'Hehir RE. Targeting the allergen-specific CD4+ T cell: Strategies for improved allergen immunotherapy. Allergy Clin. Immunol. Int. 2001; 13: 170-7.
48. Rocklin RE, Sheffer A, Greineder DK, Melmon KL. Generation of antigen-specific suppressor cells during allergy desensitization. N. Engl. J. Med. 1980; 302: 1213-19.
49. Renz H, Lack G, Saloga J et al. Inhibition of IgE production and normalization of airways responsiveness by sensitized CD8 T cells in a mouse model of allergen-induced sensitization. J. Immunol. 1994; 152: 351-60.
50. Groux H, O'Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-42.
51. Ichikawa K, Vailes LD, Pomes A, Chapman MD. Identification of a novel cat allergen: Cystatin. Int. Arch. Allergy Immunol. 2001; 124: 55-6.
52. Epton MJ, Dilworth RJ, Smith W, Thomas WR. Sensitisation to the lipid-binding apolipophorin allergen Der p 14 and the peptide Mag-1. Int. Arch. Allergy Immunol. 2001; 124: 57-60.
53. Burton MD, Blaher B, Suphioglu C, O'Hehir RE, Carbone FR, Rolland JM. T-cell receptor contact and MHC binding residues of a major rye grass pollen allergen T-cell epitope. J. Allergy Clin. Immunol. 1999; 103: 255-61.
54. De Lalla C, Sturniolo T, Abbruzzese L et al. Identification of novel T cell epitopes in Lol p5a by computational prediction. J. Immunol. 1999; 163: 1725-9.
55. Burton MD, Papalia L, Eusebius NP, O'Hehir RE, Rolland JM. Characterisation of the human T cell response to rye grass pollen allergens Lol p 1 and Lol p 5. Allergy 2002 (in press).
56. O'Hehir RE, Hoyne GF, Thomas WR, Lamb JR. House dust mite allergy: From T cell epitopes to immunotherapy. Eur. J. Clin. Invest. 1993; 23: 763-72.
57. Van Neerven RJJ, Ebner C, Yssel H, Kapsenberg ML, Lamb JR. T-cell responses to allergens: Epitope specificity and clinical relevance. Immunol. Today 1996; 17: 526-32.
58. De Silva HD, Sutherland MF, Suphioglu C et al. Human T-cell epitopes of the latex allergen Hev b 5 in health care workers. J. Allergy Clin. Immunol. 2000; 105: 1017-24.
59. Verhoef A, Lamb JR. Threshold signaling of human ThO cells in activation and anergy: Modulation of effector function by altered TCR ligand. J. Immunol. 2000; 164: 6034-40.
60. + T cells. J. Immunol. 1996; 157: 2160-5.
61. Ikagawa S, Matsushita S, Chen YZ, Ishikawa T, Nishimura Y. Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism. J. Allergy Clin. Immunol. 1996; 97: 53-64.
62. Hoyne GF, O'Hehir RE, Wraith DC, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. 1993; 178: 1783-8.
63. Hoyne GF, Jarnicki AG, Thomas WR, Lamb JR. Characterization of the specificity and duration of T cell tolerance to intranasally administered peptides in mice: A role for intramolecular epitope suppression. Int. Immunol. 1997; 9: 1165-73.
64. 2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 1998; 101: 747-54.
65. Norman PS, Ohman JL, Long AA et al. Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. 1996; 154: 1623-8.
66. Haselden BM, Kay AB, Larche M. IgE-independent MHC-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 1999; 189: 1885-94.
67. Oldfield WLG, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: A randomised controlled trial. Lancet 2002; 360: 47-53.
68. Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur. J. Immunol. 1998; 28: 914-25.
69. Marsh DG, Norman PS, Roebber M, Lichtenstein LM. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J. Allergy Clin. Immunol. 1981; 68: 449-59.
70. Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J. Allergy Clin. Immunol. 1985; 76: 397-401.
71. Ferreira F, Hirtenlehner K, Kilek A et al. Dissection of imunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: Potential use of hypoallergenic isoforms for immunotherapy. J. Exp. Med. 1996; 183: 599-609.
72. Ferreira F, Hirtenlehner K, Briza P et al. Isoforms of atopic allergens with reduced allergenicity but conserved T cell antigenicity: Possible use for specific immunotherapy. Int. Arch. Allergy Immunol. 1997; 113: 125-7.
73. Bonura A, Amoroso S, Locorotondo G et al. Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: A member of the non-specific lipid transfer protein plant family. Int. Arch. Allergy Immunol. 2001; 126: 32-40.
74. Olsson S, van Hage-Hamsten M, Whitley P. Contribution of disulphide bonds to antigenicity of Lep d 2, the major allergen of the dust mite Lepidoglyphus destructor. Mol. Immunol. 1998; 35: 1017-23.
75. Ferreira F, Ebner C, Kramer B et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: Potential use of hypoallergenic variants for immunotherapy. FASEB J. 1998; 12: 231-42.
76. Rabjohn P, West CM, Connaughton C et al. Modification of peanut allergen Ara h 3: Effects on IgE binding and T cell stimulation. Int. Arch. Allergy Immunol. 2002; 128: 15-23.
77. Helm RM, Cockrell G, Connaughton C et al. Mutational analysis of the IgE-binding epitopes of P34/Gly m Bd 30K. J. Allergy Clin. Immunol. 2000; 105: 378-84.
78. Beezhold DH, Hickey VL, Sussman GL. Mutational analysis of the IgE epitopes in the latex allergen Hev b 5. J. Allergy Clin. Immunol. 2001; 107: 1069-76.
79. Korematsu S, Tanaka Y, Hosoi S et al. C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation. J. Immunol. 2000; 165: 2895-902.
80. Hochreiter R, Hartl A, Freund J, Valenta R, Ferreira F, Thalhamer J. The influence of CpG motifs on a protein or DNA-based Th2-type immune response against major pollen allergens Bet v 1a, Phl p 2 and Escherichia coli-derived beta-galactosidase. Int. Arch. Allergy Immunol. 2001; 124: 406-10.
81. Horner AA, Van Uden JH, Zubeldia JM, Broide D, Raz E. DNA-based immunotherapeutics for the treatment of allergic disease. Immunol. Rev. 2001; 179: 102-18.